Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
CA14161Y2006
Fri, 14.06.2024
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and increased the price target from USD 3.60 to
USD 8.50.
Abstract:
Cardiol Therapeutics (Cardiol) announced excellent topline data for its
phase II open-label pilot US study (MAvERI [ … ]
Tue, 27.02.2024
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics (Cardiol) announced that the FDA has granted Orphan
Drug Designation (ODD) in the US for its lead drug candid [ … ]
Fri, 19.01.2024
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics (Cardiol) has completed >50% of patient recruitment
for CardiolRx's two lead indications, acute myocarditi [ … ]
Wed, 30.08.2023
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics has published its H1 2023 financial report. Overall
figures were in line with our expectations. The company r [ … ]
Wed, 24.05.2023
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics has published its Q1/23 financial report and business
update, which was roughly in line with our expectations. [ … ]
Wed, 24.05.2023
Cardiol Therapeutics Inc
First Berlin Equity Research has published a research update on Cardiol
Therapeutics Inc. (ISIN: CA14161Y2006). Analyst Christian Orquera
reiterated his BUY rating and maintained his USD 3.60 price target.
Abstract:
Cardiol Therapeutics has published its Q1/23 financial report and business
update, which was roughly in line with our expectations. [ … ]
Tue, 11.04.2023
Cardiol Therapeutics Inc
First Berlin Equity Research hat die Coverage von Cardiol Therapeutics Inc
(ISIN: CA14161Y2006) aufgenommen. Das Rating von Analyst Christian Orquera
ist BUY bei einem Kursziel von USD 3,60 (€3,30).
Zusammenfassung:
Cardiol Therapeutics Inc. (Cardiol) ist ein Biotech-Unternehmen mit einer
Produktpipeline im klinischen Stadium, die sich auf [ … ]
Tue, 11.04.2023
Cardiol Therapeutics Inc
First Berlin Equity Research hat die Coverage von Cardiol Therapeutics Inc
(ISIN: CA14161Y2006) aufgenommen. Das Rating von Analyst Christian Orquera
ist BUY bei einem Kursziel von USD 3,60 (€3,30).
Zusammenfassung:
Cardiol Therapeutics Inc. (Cardiol) ist ein Biotech-Unternehmen mit einer
Produktpipeline im klinischen Stadium, die sich auf [ … ]
Sat, 14.05.2022
Cardiol Therapeutics Inc.
Upcoming Investor Event:
Cardiol Therapeutics Inc. to present at digital International Investment
Forum (IIF)
On May 19, the IIF International Investment Forum will take place. At this
forum, Cardiol Therapeutics Inc. will also present its business model and
current business development.
Presentation slot:
Cardiol Therapeutics Inc. (ISIN: CA14 [ … ]
Thu, 10.02.2022
Cardiol Therapeutics Inc.
Upcoming Investor Event:
Cardiol Therapeutics to present at digital International Investment Forum
(IIF)
On February 17, the IIF International Investment Forum will take place. At
this forum, Cardiol Therapeutics will also present its business model and
current business development.
Presentation slot:
Cardiol Therapeutics Inc. (ISIN: CA14161Y2 [ … ]